Science behind the Study: Bioengineered Factor VIII — More Innovation for Hemophilia A

This editorial describes the science behind the treatment of children with hemophilia A with efanesoctocog alfa, a bioengineered recombinant factor VIII protein.

​   The New England Journal of Medicine: Search Results in Pediatrics